Evidence map›Paper›PMID 26229288›Full record

ArticleBioinformation2015

Molecular docking based screening of GABA (A) receptor inhibitors from plant derivatives.

Mohammed Marunnan Sahila, Pallikkara Pulikkal Babitha, Srinivas Bandaru, Anuraj Nayarisseri, Victor Arokia Doss

Abstract read
In one paragraph

Article in Bioinformation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mohammed Marunnan SahilaDepartment of Bioinformatics, School of Life Sciences, Karpagam University, Coimbatore 641021, India ; Department of Bioinformatics, SIAS-Centre for Scientific, Research, Safi Institute of Advanced Study(SIAS) , Rasiya Nagar, Vazhayoor East, Malappuram-673633, Kerala, India.
Pallikkara Pulikkal BabithaResearch and Development centre, Bharathiyar University,Coimbatore.641046,Tamilnadu.
Srinivas BandaruBioinformatics Research Laboratory, Eminent Biosciences, Vijaynagar, Indore - 452010, India.
Anuraj NayarisseriBioinformatics Research Laboratory, Eminent Biosciences, Vijaynagar, Indore - 452010, India.
Victor Arokia DossDepartment of Biochemistry, PSG College of Arts and Science, Coimbatore - 641 014, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

unlabelledThe present antipsychotic drugs have known to show serious concerns like extra pyramidal side effects therefore, pursuit for novel antipsychotic GABAnergic drugs has lately focused on the folkloric medicine from plant derivatives as better treatment option of schizophrenia. The present study centers to identify potential inhibitors of plant origin for GABA receptor through in silico approaches. Three compound datasets were undertaken in the study. The first set consisted of seven compounds which included Magnolol, Honokiol and other plant derivatives. The second set consisted of 16 derivatives of N-diarylalkenyl-piperidinecarboxylic acid synthesized by Zheng et al., 2006. The third dataset had thirty two compounds which were Magnolol and Honokiol analogues synthesized by Fuchs et al., 2014. All the compounds were docked at the allosteric site of the GABA (A) receptor. The compounds were further tested for ADMET and biological activity. We observed Honokiol and its derivatives demonstrated superior druglike properties than any compound undertaken in the study. Further, compound 61 [2-(4-methoxyphenyl)-4-propylphenol] of dataset three - a synthetic derivative of honokiol had better profile than its parent compound. In a possible attempt to identify compound with even better efficacious compound than 61, virtual screening was performed, 135 compounds akin to compound 61 were retrieved. Interestingly none of the 135 compounds showed better druggable properties than compound 61. Our in silico pharmacological profiling of compounds is in coherence and is complemented by the findings of Fuchs et al, which also revealed compound 61 to be the good potentiator of GABA receptor. ABBREVIATIONS: GABA (A) R - Gamma Amino Butyric Acid Receptor, subtype A, GPCR - G Protein Coupled Receptor, OPLS - Optimized Potentials for Liquid Simulations, PDB - Protein Data Bank, PLP - Piece wise Linear Potential, T.E.S.T - Toxicity Estimation Software Tool, TCM - Traditional Chinese Medicine.

Indexed as

GABA inhibitorsin silico Pharmacological profilingPlant derivativesSchizophrenia

Identifiers

PMID26229288
PMCPMC4512002

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.